Geron Returns to Quarterly Profit as Rytelo Drives Q3 Revenue Growth
Photo: TokenPost
Geron Corporation posted a quarterly profit in Q3 2026 as revenue growth from its blood cancer drug Rytelo helped reverse a run of quarterly losses. Shares gained more than 10% in early premarket trading Wednesday, Nov. 4. Geron markets imetelstat as Rytelo. The results followed the company’s plan to end a late-stage study of the drug after efficacy concerns. Geron shares fell more than 20% on Oct. 28. The company’s plan to stop the late-stage study followed concerns about the drug’s efficacy. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
